In vivo visualization of transplanted pancreatic islets by MRI: comparison between in vivo , histological and electron microscopy findings

Department of Morphological and Biomedical Sciences, University of Verona, Strada Le Grazie 8, Verona, Italy.
Contrast Media & Molecular Imaging (Impact Factor: 2.87). 05/2009; 4(3):135-42. DOI: 10.1002/cmmi.274
Source: PubMed

ABSTRACT The aim of the work was to compare in vivo MRI visualization of pancreatic islets labeled with clinical-grade superparamagnetic iron oxide (SPIOs) contrast agents with ex vivo examination of liver tissue in an experimental model of marginal mass transplantation in rats. Seven hundred IEq (Islet Equivalent) from Wistar rats, labeled by incubation with Endorem or Resovist, were transplanted into Sprague-Dawley rats through the portal vein. Liver MR images of recipient rats were acquired at different time points (3-42 days) after transplantation. Animals were sacrificed during this period and their livers were excised and prepared for histology and electron microscopy. Hypointense spots originating from iron particles were observed in MR images. The number of separate spots was counted. Three days after transplantation one spot for every three or four transplanted islets was observed. Seven days after transplantation, histological sections showed the presence of iron within pancreatic islets. The time course of MR images showed a decrease in the number of spots, at 42 days, amounting to 65 and 22% of the initial value, for Resovist and Endorem respectively, while no immunopositive endocrine cells were detected in histological slices. The present work shows that pancreatic islets can be labeled using clinically approved SPIO contrast agents and visualized using in vivo MRI with high sensitivity, consistently with findings in the literature. Differently from reports in the literature, our findings indicate that iron particles could last in the liver for long periods, independently of the presence of intact pancreatic islets.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In vivo magnetic resonance imaging (MRI) of iron-labeled pancreatic islets (PIs) transplanted into the liver is still challenging in humans. The aim of this study was to develop and evaluate a double contrast method for the detection of PIs labeled with superparamagnetic iron oxide (SPIO) nanoparticles. A double-echo three-dimensional (3D) spoiled gradient echo sequence was adapted to yield a sub-millisecond first echo time using variable echo times and highly asymmetric Cartesian readout. Positive contrast was achieved by conventional and relative image subtraction. Experiments for cell detection efficiency were performed in vitro on gelatin phantoms, in vivo on a Lewis rat and on a patient 6 months after PI transplantation. It was demonstrated that the proposed method can be used for the detection of transplanted PIs with positive contrast in vitro and in vivo. For all experiments, relative subtraction yielded comparable and in some cases better contrast than conventional subtraction. For the first time, positive contrast imaging of transplanted human PIs was performed in vivo in patients. The proposed method allows 3D data acquisition within a single breath-hold and yields enhanced contrast-to-noise ratios of transplanted SPIO labeled pancreatic islets relative to negative contrast images, therefore providing improved identification.
    MAGMA Magnetic Resonance Materials in Physics Biology and Medicine 11/2013; DOI:10.1007/s10334-013-0422-3 · 1.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this review, the applications of magnetic nanoparticles in biomedicine are summarized and introduced in three parts. (1) A short description of magnetic nanoparticles is explained. (2) Applications of magnetic nanoparticles in biomedicine are summarized. In biology, new progress of the magnetic separation techniques based on magnetic nanoparticles is discussed. In medicine, the magnetic nanoparticles as therapeutic agents (particularly as a hyperthermia agent, a targeted drug delivery carrier, and a magnetofection agent) as well as contrast agents in magnetic resonance imaging (MRI) are explained in detail. (3) A discussion and remarking conclusion of magnetic nanoparticles in biomedical applications are described. Finally, a perspective of the magnetic nanoparticles in biomedicine in future is also described.
    Nano brief reports and reviews 11/2011; 05(05). DOI:10.1142/S1793292010002165 · 1.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: While a few studies have demonstrated the benefit of PEGylation in islet transplantation, most have employed renal subcapsular models and none have performed direct comparisons of islet mass in intraportal islet transplantation using islet magnetic resonance imaging (MRI). In this study, our aim was to demonstrate the benefit of PEGylation in the early post-transplant period of intraportal islet transplantation with a novel algorithm for islet MRI. Islets were PEGylated after ferucarbotran labeling in a rat syngeneic intraportal islet transplantation model followed by comparisons of post-transplant glycemic levels in recipient rats infused with PEGylated (n = 12) and non-PEGylated (n = 13) islets. The total area of hypointense spots and the number of hypointense spots larger than 1.758 mm (2) of PEGylated and non-PEGylated islets were quantitatively compared. The total area of hypointense spots (P<0.05) and the number of hypointense spots larger than 1.758 mm (2) (P<0.05) were higher in the PEGylated islet group 7 and 14 days post translation (DPT). These results translated into better post-transplant outcomes in the PEGylated islet group 28 DPT. In validation experiments, MRI parameters obtained 1, 7, and 14 DPT predicted normoglycemia 4 wk post-transplantation. We directly demonstrated the benefit of islet PEGylation in protection against nonspecific islet destruction in the early post-transplant period of intraportal islet transplantation using a novel algorithm for islet MRI. This novel algorithm could serve as a useful tool to demonstrate such benefit in future clinical trials of islet transplantation using PEGylated islets.
    Islets 02/2014; 6(1). DOI:10.4161/isl.27827 · 1.55 Impact Factor